In the News
Can GAP double the number of patients in Alzheimer’s trials?
Curing diseases requires new drugs. Getting those new drugs approved by regulators requires data from successful clinical trials. Those trials depend on patients, and right now getting those patients is a challenge for many sponsor companies. According to research performed on recruitment, 85 percent of trials are delayed due to enrollment issues and more than […]
Read more »Minority Participation in Clinical Trials can Help Everyone Fight Alzheimer’s
Growing up as an African-American in the South over 75 years ago, my family didn’t have the access to medical care we do today. One event from my childhood changed my life. My mother went to the doctor’s office. She was quite ill and needed help. The doctor said she had to wait to be […]
Read more »Patient Advocacy Groups Welcome 40% Increase in Alzheimer’s NIH Research Funds Authorized by Congress
The U.S. Congress last week authorized an additional 40 percent in funds for Alzheimer’s disease (AD) research, boosting the fiscal 2017 total by $400 million to nearly $1.4 billion as part of a $2 billion year-over-year increase for the National Institutes of Health (NIH). The final package won praise from the nonprofit Global Alzheimer’s Platform Foundation (GAP), […]
Read more »Hope to Prevent Alzheimer’s? Grab the Olive Oil and Hop on a Treadmill
Ann Poehler’s strides quicken on the treadmill. Her feet pound. Her heart races from 150 to 160 beats per minute and more. A plastic tube jutting from the Prairie Village woman’s mouth feeds carbon dioxide levels to a computer here inside the University of Kansas Alzheimer’s Disease Center. The computer records every respiration while an exercise […]
Read more »National Survey Finds that a Majority of Americans Would Consider Participating in an Alzheimer’s Clinical Trial
A recent online survey conducted by Harris Poll found that nearly 60% of Americans are definitely willing or willing to consider taking part in a clinical trial for Alzheimer’s. This promising statistic is good news for researchers; however, obtaining qualified trial participants has been one of the greatest challenges in getting clinical trials off the […]
Read more »